Filtered By:
Source: American Heart Journal
Procedure: Angioplasty
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 76 results found since Jan 2013.
The need to know crude event rates in meta-analysis
Numerous reports have recently been aimed at comparing outcomes between on-pump and off-pump coronary artery bypass grafting (CABG). Among these, the meta-analysis by Palmerini et al compared percutaneous coronary intervention with CABG using a network design that included 1 patient group receiving percutaneous coronary intervention (n = 4,653) and 2 patient groups in whom CABG was performed either on-pump (n = 10,957) or off-pump (n = 7,119). The rate of stroke at 30 days was the main end point.
Source: American Heart Journal - July 26, 2013 Category: Cardiology Authors: Andrea Messori, Valeria Fadda, Dario Maratea, Sabrina Trippoli Tags: Letters to the Editor Source Type: research
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial
Conclusions: RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.
Source: American Heart Journal - October 18, 2013 Category: Cardiology Authors: Giora Weisz, Ramin Farzaneh-Far, Ori Ben-Yehuda, Bernard DeBruyne, Gilles Montalescot, Amir Lerman, Ehtisham Mahmud, Karen P. Alexander, E. Magnus Ohman, Harvey D. White, Ann Olmsted, Gennyne A. Walker, Gregg W. Stone Tags: Trial Design Source Type: research
Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: The RADIAL PUMP UP Registry
Background: The role of intraaortic balloon pump (IABP) during percutaneous coronary intervention (PCI) in high-risk acute patients remains debated. Device-related complications and the more complex patient management could explain such lack of clinical benefit. We aimed to assess the impact of transradial versus transfemoral access for PCI requiring IABP support on vascular complications and clinical outcome.Methods: We retrospectively analyzed 321 consecutive patients receiving IABP support during transfemoral (n = 209) or transradial (n = 112) PCI. Thirty-day net adverse clinical events (NACEs) (composite of postprocedu...
Source: American Heart Journal - October 14, 2013 Category: Cardiology Authors: Enrico Romagnoli, Maria De Vita, Francesco Burzotta, Bernardo Cortese, Giuseppe Biondi-Zoccai, Francesco Summaria, Roberto Patrizi, Chiara Lanzillo, Valerio Lucci, Caterina Cavazza, Fabio Tarantino, Giuseppe M. Sangiorgi, Ernesto Lioy, Filippo Crea, Sunil Tags: Interventional Cardiology Source Type: research
Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry
Conclusions: The prognosis of patients older than 80 years treated with primary PCI for STEMI was relatively unchanged during the 10-year inclusion period, despite changes in patient characteristics and treatment. Advanced age increased the risk of adverse events, but survivors of the early phase after PCI had a slightly improved prognosis compared with the general population.
Source: American Heart Journal - February 27, 2014 Category: Cardiology Authors: Matthijs A. Velders, Stefan K. James, Berglind Libungan, Giovanna Sarno, Ole Fröbert, Jörg Carlsson, Martin J. Schalij, Per Albertsson, Bo Lagerqvist Tags: Acute Ischemic Heart Disease Source Type: research
Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population
Conclusion: Among Korean population undergoing contemporary PCI, women have a significantly higher risk of short- and long-term major cardiovascular events than do men but have better long-term survival.
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park Tags: Interventional Cardiology Source Type: research
CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Conclusion: The POPular Genetics study is the first large-scale trial comparing CYP2C19 genotype–guided antiplatelet therapy to a nontailored strategy in terms of net clinical benefit, safety, and cost-effectiveness.
Source: American Heart Journal - March 24, 2014 Category: Cardiology Authors: Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper, Khalid Qaderdan, Maycel Ishak, Rianne S. Ruitenbeek, Folkert W. Asselbergs, Arnoud W.J. van ‘t Hof, Willem J.M. Dewilde, Fabrizio Spanó, Jean-Paul R. Herrman, Johannes C. Kelder, Maarten J. P Tags: Trial Design Source Type: research
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensiv...
Source: American Heart Journal - April 14, 2014 Category: Cardiology Authors: Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann Tags: Acute Ischemic Heart Disease Source Type: research
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study
Conclusion ANTARCTIC is a nationwide, prospective, open-label study testing a strategy of platelet function monitoring with dose and drug adjustment to reduce ischemic and bleeding complications in elderly ACS patients undergoing coronary stenting.
Source: American Heart Journal - October 31, 2014 Category: Cardiology Source Type: research
Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Marco Valgimigli Background Transradial intervention (TRI) and bivalirudin infusion compared with transfemoral coronary intervention or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors decrease bleeding complications in patients with acute coronary syndromes (ACS). Although bleeding is thought to be associated with worse outcomes, it remains unclear whether TRI and bivalirudin both independently lower ischemic or combined ischemic and bleeding complications in ACS patients undergoing contemporary invasive management....
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research
Radial versus Femoral Access for Elderly Patients with Acute Coronary Syndrome undergoing Coronary Angiography and Intervention: Insights from the RIVAL Trial
Conclusions Consistent with the overall RIVAL trial population, elderly patients undergoing cardiac catheterization have lower rates of major bleeding or access site complications and higher rates of access site crossover with radial access compared to femoral access.
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research
Percutaneous Left Ventricular Assist Device for High Risk Percutaneous Coronary Interventions. Real World versus Clinical Trial Experience
Conclusions USpella provides a real world and contemporary estimation of the type of procedures and outcomes of high-risk patients undergoing PCI supported by Impella 2.5. Despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial.
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research
High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction
Conclusions Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience
Conclusions USpella provides a real-world and contemporary estimation of the type of procedures and outcomes of high-risk patients undergoing PCI supported by Impella 2.5. Despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial.
Source: American Heart Journal - September 19, 2015 Category: Cardiology Source Type: research
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research
